LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

12.3 -1.99

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.28

Massimo

12.8

Metriche Chiave
By Trading Economics
Entrata	-1.5M -74M
Margine di Profitto	-1,582.642
Dipendenti	205
EBITDA	1.7M -72M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+66.83% upside

Dividendi
By Dow Jones
Utili prossimi	10 nov 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	89M 1.8B
Apertura precedente	14.29
Chiusura precedente	12.3

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2025, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 set 2025, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 set 2025, 21:59 UTC

Utili

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 set 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

17 set 2025, 23:39 UTC

Discorsi di Mercato

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 set 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 set 2025, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 set 2025, 21:00 UTC

Utili

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 set 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

17 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 set 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 set 2025, 18:43 UTC

Discorsi di Mercato

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 set 2025, 18:38 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 set 2025, 18:20 UTC

Discorsi di Mercato

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 set 2025, 18:14 UTC

Discorsi di Mercato

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 set 2025, 17:59 UTC

Discorsi di Mercato

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 set 2025, 17:15 UTC

Acquisizioni, Fusioni, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 set 2025, 17:06 UTC

Acquisizioni, Fusioni, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 set 2025, 16:51 UTC

Utili

Correct: Exor 1H Net Loss -EUR624M

17 set 2025, 16:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 16:34 UTC

Discorsi di Mercato

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 set 2025, 16:25 UTC

Utili

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 set 2025, 16:23 UTC

Utili

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

66.83% in crescita

Previsioni per 12 mesi

Media 20.92 USD 66.83%

Alto 30 USD

Basso 10 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 13 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.